288307-57-3
Chemical Structure
A5G27
- CAS No.: 288307-57-3
- Formula:C77H120N18O17
- Molecular Weight:1569.89
InChIKey: OHHXYKIHAOADOY-MFQRXDNOSA-N
SMILES: O=C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC(N)=O)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N
Biological Activity: A5G27 is a laminin-derived peptide ligand and CD44 antagonist that binds to CD44, CD44v3, and CD44v6, driving receptor-mediated endocytosis and internalization into CD44-expressing cells. A5G27 alleviates mechanical hyperalgesia induced by substances such as carrageenan and Hyaluronidase. A5G27 exhibits antitumor activity. A5G27 can be used in research on cancer, inflammatory pain, and wound healing[1][2][3][4][5][6][7].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A5G27 | A5G27 is a laminin-derived peptide ligand and CD44 antagonist that binds to CD44, CD44v3, and CD44v6, driving receptor-mediated endocytosis and internalization into CD44-expressing cells. A5G27 alleviates mechanical hyperalgesia induced by substances such as carrageenan and Hyaluronidase. A5G27 exhibits antitumor activity. A5G27 can be used in research on cancer, inflammatory pain, and wound healing. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pesarrodona M, et al. Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. International journal of pharmaceutics. 2014 Oct 01;473(1-2):286-95.
- [2]. Turley EA, et al. RHAMM and CD44 peptides-analytic tools and potential drugs. Frontiers in bioscience (Landmark edition). 2012 Jan 01;17(5):1775-94.
- [3]. Ferrari LF, et al. Extracellular matrix hyaluronan signals via its CD44 receptor in the increased responsiveness to mechanical stimulation. Neuroscience. 2016 Jun 02;324:390-8.
- [4]. Pesarrodona M, et al. Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Nanoscale. 2017 May 18;9(19):6427-6435.
- [5]. Bonet IJ. Mechanisms mediating high-molecular-weight hyaluronan-induced antihyperalgesia. Journal of Neuroscience. 2020 Aug 19;40(34):6477-88.
- [6]. Milošević N, et al. Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines. Frontiers in medical technology. 2022;4:846065.
- [7]. Kulkarni N, et al. Peptide-Chitosan Engineered Scaffolds for Biomedical Applications. Bioconjugate chemistry. 2021 Mar 17;32(3):448-465.
